Asset Details
Do you wish to reserve the book?
QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Do you wish to request the book?
QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
2024
Overview
Background
Cyclin-dependent kinases (CDK) 4/6 inhibitors have significantly improved outcomes for patients with ER+/HER2− breast cancer. Nevertheless, they differ from each other in terms of chemical, biological, and pharmacological features, as well as toxicity profiles. We aim to determine whether QTc prolongation is caused by CDK4/6i in general or if it is associated with ribociclib only.
Methods
We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing the prevalence of QTc prolongation as an adverse event in HR+ breast cancer patients treated with CDK4/6i vs those without CDK4/6i. We pooled relative risk (RR) and mean difference (MD) with 95% confidence interval (CI) for the binary endpoint of QT prolongation.
Results
We included 14 RCTs comprising 16 196 patients, of whom 8576 underwent therapy with CDK4/6i. An increased risk of QTc prolongation was associated with the use of CDK4/6i (RR = 2.35, 95% CI = 1.67 to 3.29, P < .001; I2 = 44%). Subgroup analyses revealed a significant increase in the QTc interval for the ribociclib and palbociclib cohorts. The ribociclib subgroup showed a relative risk of 3.12 (95% CI = 2.09 to 4.65, P < .001; I2 = 12%), whereas the palbociclib subgroup had a relative risk of 1.51 (95% CI = 1.05 to 2.15, P = .025; I2 = 0%).
Conclusion
Palbociclib was associated with QTc prolongation; however, the relative risk for any grade QTc was quantitively twice with ribociclib. Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.
Publisher
Oxford University Press
Subject
Aminopyridines - administration & dosage
/ Aminopyridines - adverse effects
/ Aminopyridines - therapeutic use
/ Breast Neoplasms - drug therapy
/ Cyclin-Dependent Kinase 4 - antagonists & inhibitors
/ Cyclin-Dependent Kinase 6 - antagonists & inhibitors
/ Female
/ Humans
/ Kinases
/ Long QT Syndrome - chemically induced
/ Piperazines - adverse effects
/ Piperazines - therapeutic use
/ Protein Kinase Inhibitors - administration & dosage
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Purines - administration & dosage
/ Pyridines - administration & dosage
